Hasil Pencarian - Frederic Triebel

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

    Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma oleh Christian Mueller, Frederic Triebel, Chrystelle Brignone, Adnan Khattak, Amitesh Roy

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

    790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head a... oleh Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Leora Horn, Frederic Triebel, Enric Carcereny, Margarita Majem, Bernard Doger, Julio Peguero, Pawan Bajaj, Patricia Roxburgh, Chrystelle Brignone

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

    948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC oleh Christian Mueller, Frederik Marmé, Luc Dirix, Frederic Triebel, Hans Wildiers, Peter Vuylsteke, Chrystelle Brignone, Jens Huober, Sherko Kümmel, Anne Armstrong, Eveline De Cuypere, Florence Dalenc, Steven Chan, Carolina Pia Schröder, Jean-Philippe Jacquin, Etienne Brain, Zsuzsanna Pápai

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

    595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab oleh Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Frederic Triebel, Enric Carcereny, Ewa Kalinka, Margarita Majem, Bernard Doger, Julio Peguero, Chrystelle Brignone, Igor Bondarenko, Wade T Iams, Manuel Cobo Dols, Grygorii Ursol, Gema Garcia Ledo, Laia Vilà Martinez

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Immunophenotyping of Peripheral Blood Mononuclear Cells in Septic Shock Patients With High-Dimensional Flow Cytometry Analysis Reveals Two Subgroups With Differential Responses to Immunostimulant Drugs

    Immunophenotyping of Peripheral Blood Mononuclear Cells in Septic Shock Patients With High-Dimensional Flow Cytometry Analysis Reveals Two Subgroups With Differential Responses to... oleh Ya Wang, Ya Wang, Brian Gloss, Benjamin Tang, Benjamin Tang, Suat Dervish, Brigitte Santner-Nanan, Christina Whitehead, Kristy Masters, Kristen Skarratt, Sally Teoh, Stephen Schibeci, Nicole Fewings, Chrystelle Brignone, Frederic Triebel, David Booth, Anthony McLean, Marek Nalos, Marek Nalos

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study

    Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1... oleh Matthew G. Krebs, MD, Martin Forster, MD, PhD, Margarita Majem, MD, PhD, Julio Peguero, MD, Wade Iams, MD, Tim Clay, MD, Patricia Roxburgh, MD, PhD, Bernard Doger, MD, PhD, Pawan Bajaj, MD, Andres Barba, MD, Suvini Perera, MS, Christian Mueller, MS, Frédéric Triebel, MD, PhD

    Diterbitkan 2024-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

    New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016 oleh Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky, Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey, Charles G. Drake, Gordon J. Freeman, Ramy Ibrahim, Salil Patel, Daniel S. Chen

    Diterbitkan 2017-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: